Quantum News
Sign InSign Up
Back to News
research

Rhythm Pharmaceuticals, Inc. (RYTM) Discusses Topline Results and Insights from Phase 3 EMANATE Trial Transcript

Seeking Alpha
Loading...
2 min read
0 likes
⚡ Quantum Brief
Rhythm Pharmaceuticals announced Phase 3 EMANATE trial top-line results on March 16, 2026, evaluating its lead drug for rare genetic obesity disorders. The call featured CEO David Meeker and Chief Scientific Officer Alastair Garfield. The trial assessed efficacy and safety in patients with POMC or LEPR deficiency, targeting weight regulation via melanocortin-4 receptor (MC4R) pathway activation. Detailed data was presented in a concurrent press release and investor slides. Analysts from TD Cowen, BofA Securities, and Goldman Sachs participated, questioning trial design, endpoints, and commercialization plans. The company emphasized the drug’s potential as a first-in-class therapy for untreated populations. Forward-looking statements highlighted regulatory submission timelines and market potential, though risks include clinical uncertainty and competitive pressures. Investors were directed to the company’s SEC filings for full risk disclosures. The call underscored the trial’s pivotal role in Rhythm’s pipeline, with financial implications discussed by CFO Hunter Smith. Next steps include regulatory discussions and potential FDA/EMA filings.
AI Audio Summary
0:00 / 0:00
Click to play
christian-wiediger-c3ZWXOv1Ndc-unsplash.jpg
Quantum News · Media Library

Understand this faster with AI

ChatGPTAsk ChatGPTPerplexityResearch with PerplexityClaudeExplain with ClaudeGrokDiscuss on Grok

SA Transcripts159K FollowersFollow5ShareSaveCommentsPlay Earnings CallPlay Earnings Call Rhythm Pharmaceuticals, Inc. (RYTM) Discusses Topline Results and Insights from Phase 3 EMANATE Trial March 16, 2026 4:30 PM EDT Company Participants David Connolly - Head of Investor Relations & Corporate CommunicationsDavid Meeker - Chairman, President & CEO Conference Call Participants Philip Nadeau - TD Cowen, Research DivisionTazeen Ahmad - BofA Securities, Research DivisionDerek Archila - Wells Fargo Securities, LLC, Research DivisionCorinne Jenkins - Goldman Sachs Group, Inc., Research DivisionJonathan Wolleben - Citizens JMP Securities, LLC, Research DivisionLisa Walter - RBC Capital Markets, Research Division Presentation Operator Good day, and thank you for standing by. Welcome to the Rhythm Pharmaceuticals Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Dave Connolly, Investor Relations. Please go ahead. David ConnollyHead of Investor Relations & Corporate Communications Thank you, Daniel, and good afternoon, everyone, and welcome. This afternoon, we issued a press release with the Phase III top line results for our EMANATE trial. You can access the press release as well as the slides that we will be reviewing today by going to the Investors section of our website. Listed on Slide 3 are the speakers for today's call. David Meeker, Chair, President and Chief Executive Officer, will walk through these data. And Dr. Alastair Garfield, our Chief Scientific Officer; and Hunter Smith, our CFO, are available to answer questions on this call as well. Before we get started, I would like to remind everyone that these statements we make on this conference call will include forward-looking statements. Actual events or results could differ materially from those expressed or implied by any forward-looking statements as a result of various risks, uncertainties and other factors, including those set forth in the risk factors in our Risk Factors

Read Original

Tags

drug-discovery
quantum-finance

Source Information

Source: Seeking Alpha

Discussion

0 professional contributions

Sign in to join this professional discussion.

Be the first to add a constructive contribution.